ANGLE plc (GB:AGL) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ANGLE plc has unveiled promising new data at the AACR Special Conference, highlighting its Parsortix-based PD-L1 assay’s potential in improving personalized treatment for lung cancer patients. This innovative liquid biopsy technology enables non-invasive, ongoing monitoring of PD-L1 status in circulating tumor cells, which could offer a more dynamic and comprehensive assessment of tumor heterogeneity compared to traditional tissue biopsies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.